Teva Pharmaceutical (NYSE:TEVA) finally delivered on a good news show, as investors welcomed the positive news flow. Shares jumped a quarter from their lows on the back of three positive news developments.
In the time frame of just two days Teva announced a new CEO, a sizeable asset sale, while it could report favourable news from the FDA as well. This news flow appears to have put a bottom under the shares, as Teva needs to do much more work in order to improve the situation from here.
The good news is that the company is moving swiftly, a comforting sign for investors.
